NCT04860947Active, not recruiting
Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
Assessment of Serum Neurofilament-light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) Levels, Atrophy of the Macular Ganglion Cell Complex (GCC) by Optical Coherence Tomography (OCT) and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in Multiple Sclerosis Patients
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
The investigators hypothesize that serum neurofilament-light chain (NfL) levels at baseline and decrease of the macular ganglion cell complex (GCC) thickness at one year vs. baseline are as good as progression of whole brain atrophy at one year vs. baseline to predict later evolution of neurological disability in multiple sclerosis patients.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 200 (actual)
- First submitted
- 16 Apr 2021
- Start date
- 25 Jun 2019
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Diseases
- Multiple sclerosis
- NCT number
- NCT04860947
What you commit to
- Study type: Observational
- Participants enrolled: 200
- From 25 Jun 2019 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patient is in an exclusion period determined by a previous study.
Other illness
- The patient has a severe psychiatric illness
Other
- The patient is under judicial protection.
- The patient refuses to sign the consent.
- It is impossible to correctly inform the patient (Inability to understand the study, language problem).
- The patient is pregnant or breast-feeding.
- Patient has a bilateral optic neuritis or other significant ophthalmological antecedent.
- Patient with MRI contra-indications.
- patient has a contraindication to gadolinium injection
- The patient has bilateral optic neuritis or other significant ophthalmological antecedent
- Patient is having a relapse or has had a relapse in the last 3 months
- The patient has severe chronic alcoholism
Who the study is looking for
- The patient has been correctly informed.
- The patient must have given their informed and signed consent.
- The patient must be insured or beneficiary of a health insurance plan.
- The patient is at least (≥)18 years old.
- The patient has experienced a CIS, has currently a RRMS or progressive MS with:
- Less than 10 years of disease duration;
- With or without DMD;
- EDSS score 0 - 7.0.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Nîmes Coordinator of this site? Confirm its status | Nîmes | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.